NCT02766582View on ClinicalTrials.gov

Phase II: Pembrolizumab/Carboplatin/Taxol in Epithelial Ovary Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

October 31, 2016

Primary Completion Date

May 31, 2022

Study Completion Date

December 30, 2023

Conditions
Ovarian Cancer
Interventions
DRUG

Pembrolizumab

IV every 21 days at 200 mg

DRUG

Carboplatin

IV every 21 days

DRUG

Paclitaxel

IV infusion (80mg/m2) every 7 days for 6 cycles

Trial Locations (2)

53226

Medical College of Wisconsin and Froedtert Hospital, Milwaukee

Unknown

Cleveland Clinic, Cleveland

All Listed Sponsors
collaborator

The Cleveland Clinic

OTHER

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Medical College of Wisconsin

OTHER

NCT02766582 - Phase II: Pembrolizumab/Carboplatin/Taxol in Epithelial Ovary Cancer | Biotech Hunter | Biotech Hunter